tirzepatide stopped losing weight caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Why I’m Not Losing Weight

The injectable versions, sold under the brand names Mounjaro and Zepbound, remain the only forms that have passed clinical trials, earned regulatory approval, and demonstrated consistent results in peer-reviewed research

The intent reported is to soften appetite rebound and reduce the abruptness of GLP-1 receptor withdrawal

Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease

Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

It operates under the principle of shared risk and cost-sharing, where policyholders pool their resources to cover the medical expenses of the entire group

doi:10.2337/db14-0758 41